Average Co-Inventor Count = 7.29
ph-index = 17
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Forma Therapeutics, Inc. (43 from 125 patents)
2. Valo Health, Inc. (18 from 29 patents)
3. Genentech, Inc. (10 from 3,212 patents)
4. Kymera Therapeutics, Inc. (10 from 33 patents)
5. Neurogen Corporation (9 from 305 patents)
6. Forma Tm, LLC (9 from 10 patents)
7. Valo Early Discovery, Inc. (8 from 15 patents)
8. Other (4 from 832,448 patents)
9. Novo Nordisk Healthcare Ag (4 from 88 patents)
10. H. Lee Moffitt Cancer Center and Research Institute, Inc. (1 from 289 patents)
105 patents:
1. 12336981 - Compounds and compositions for the inhibition of NAMPT
2. 12304904 - Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
3. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
4. 12258341 - IRAK degraders and uses thereof
5. 12213969 - 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
6. 12150995 - IRAK degraders and uses thereof
7. 12122778 - Activating pyruvate kinase R
8. 12097261 - CDK2 degraders and uses thereof
9. 12091411 - IRAK degraders and uses thereof
10. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
11. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound
12. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound
13. 11932624 - MDM2 degraders and uses thereof
14. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
15. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors